CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR 与 TCR：谁赢得这场较量
英文原题：Who wins the combat, CAR or TCR?
查看英文原题
Who wins the combat, CAR or TCR?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近几十年来，CAR-T（CAR-T）细胞疗法因在治疗 B 细胞血液系统恶性肿瘤方面疗效显著且取得突破而受到广泛关注。尽管 CAR-T 疗法在临床上取得出色成绩，多数接受治疗的患者仍会在输注后复发。CAR 是基于 T 细胞受体（TCR）复合物和与 T 细胞活化相关的共刺激分子构建的；然而，CAR 与内源性 TCR 在敏感性、信号通路、杀伤机制和功能表现方面的异同，尚未得到充分了解。本综述从多个方面平行比较 CAR 和 TCR，并探讨现有发现如何为深入理解 CAR-T 疗法、提高其疗效提供新见解。
展开英文摘要原文
Chimeric antigen receptor T (CAR-T) cell therapy has drawn increasing attention over the last few decades given its remarkable effectiveness and breakthroughs in treating B cell hematological malignancies. Even though CAR-T cell therapy has outstanding clinical successes, most treated patients still relapse after infusion.
CARs are derived from the T cell receptor (TCR) complex and co-stimulatory molecules associated with T cell activation; however, the similarities and differences between CARs and endogenous TCRs regarding their sensitivity, signaling pathway, killing mechanisms, and performance are still not fully understood. In this review, we discuss the parallel comparisons between CARs and TCRs from various aspects and how these current findings might provide novel insights and contribute to improvement of CAR-T cell therapy efficacy.
论文信息
- 作者
- Yun K、Siegler EL、Kenderian SS
- 第一作者单位
- T Cell Engineering, Mayo Clinic, Rochester, MN, USA.United States
- 通讯作者单位
- T Cell Engineering, Mayo Clinic, Rochester, MN, USA. Kenderian.Saad@mayo.edu.United States
- 文献类型
- 综述 · 美国 NIH 资助研究
- 期刊
- Leukemia2023 Oct
- 原文标识
- PubMed 37626090 · DOI 10.1038/s41375-023-01976-z